MARATTO

article

Antimicrobial Resistance Mechanisms of Clinical Isolates of Escherichia coli obtained over 3-year period from 2021 to 2023 in Uganda.

2026Open accessMakerere University

Abstract

Introduction There is a high prevalence of antibiotic-resistant clinical isolates of Escherichia coli in Uganda but there is limited information on the mechanisms of resistance. Objective Mechanisms of antibiotic-resistant E. coli clinical isolates from the Clinical Microbiology Laboratory, Department of Medical Microbiology of Makerere University were determined. Methods The cross-sectional study from 2021 to 2023 was conducted on archived clinical isolates of E. coli isolates from the most prevalent samples; blood, pus swab, rectal swab, urine, and wound swab. E. coli was re-identified by phenotypic methods; Gram stain microscopy, culture and biochemical tests. Antibiotic susceptibility testing and resistance phenotypes; extended spectrum β-lactamase (ESBL), AmpC and carbapenemase production were determined by Kirby Bauer disk diffusion method. Descriptive statistics were used for the results. Results Of the N= 213 isolates of E. coli tested, n=166 (77.9%) were ESBL positive, n=39 (18.3%) was AmpC positive and 3 (1.4%) were confirmed as carbapenemase producing. Conclusion Therefore, ESBL production is the most common mechanism of antibiotic resistance of E. coli isolates from the Clinical Microbiology Laboratory of Makerere University.

Research topics

  • Antibiotic Resistance in Bacteria
  • Bacterial Identification and Susceptibility Testing
  • Antibiotic Use and Resistance

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1099/acmi.0.001066.v2

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.